de Bartolomeis Andrea, Fagiolini Andrea, Vaggi Marco, Vampini Claudio
Section of Psychiatry and Treatment Resistant Psychosis, Department of Neuroscience, University of Naples Federico II, Naples, Italy.
Department of Molecular and Developmental Medicine, School of Medicine, University of Siena, Siena, Italy.
Neuropsychiatr Dis Treat. 2016 Jan 11;12:99-108. doi: 10.2147/NDT.S96214. eCollection 2016.
This survey of Italian psychiatrists was conducted to better define drivers of schizophrenia treatment choice in real-life practice, particularly for use of long-acting injectable (LAI) antipsychotics.
Between October 15 and December 15, 2014, 1,000 surveys were sent to psychiatrists who treat schizophrenic patients; 709 completed questionnaires were analyzed (71% response rate).
The two most important factors determining therapy success were efficacy (75% of responses) and tolerability (45%) followed by global functioning (24%) and quality of life (17%). LAI antipsychotics were most often used to facilitate regular treatment monitoring (49%), and 41% of psychiatrists thought that patients with low adherence who had failed oral therapy were well-suited for LAI antipsychotics. Only 4% of respondents saw LAI antipsychotics as appropriate for patients without other therapeutic options.
Although efficacy and tolerability were the most common factors used to evaluate treatment success in schizophrenia, psychiatrists also consider QoL and global functioning to be important.
开展此次针对意大利精神科医生的调查，以便更明确现实临床实践中精神分裂症治疗选择的驱动因素，尤其是长效注射用抗精神病药物的使用情况。
2014年10月15日至12月15日期间，向治疗精神分裂症患者的精神科医生发放了1000份调查问卷；对709份完成的问卷进行了分析（回复率为71%）。
决定治疗成功的两个最重要因素是疗效（75%的回复）和耐受性（45%），其次是整体功能（24%）和生活质量（17%）。长效注射用抗精神病药物最常用于便于定期治疗监测（49%），41%的精神科医生认为口服治疗失败的依从性差的患者适合使用长效注射用抗精神病药物。只有4%的受访者认为长效注射用抗精神病药物适用于没有其他治疗选择的患者。
虽然疗效和耐受性是评估精神分裂症治疗成功最常用的因素，但精神科医生也认为生活质量和整体功能很重要。
